Celecoxib increased cardiovascular events in patients with colorectal adenomas

Juurlink, David N.
July 2005
ACP Journal Club;Jul/Aug2005, Vol. 143 Issue 1, p8
Academic Journal
This article presents information on a study related to celecoxib that increases cardiovascular events in patients with colorectal adenomas. Patients who received 800 mg/d of celecoxib had a greater risk for the cardiovascular composite endpoint than did patients who received placebo. The risk decreased slightly when angina compared with placebo, 800 mg/d of celecoxib was also associated with increased cardiovascular death or nonfatal myocardial infarction. Risks for cardiovascular events were increased with 400 mg/d of celecoxib, but only reached borderline statistical significance for cardiovascular death, or nonfatal myocardial infarction, or stroke.


Related Articles

  • MI risk prompts rofecoxib withdrawal. Thompson, Cheryl A. // American Journal of Health-System Pharmacy;11/1/2004, Vol. 61 Issue 21, p2234 

    The article presents information on the withdrawal of rofecoxib from the U.S. market. The withdrawal of rofecoxib leaves the U.S. market with two cyclooxygenase type 2 (COX-2) inhibitors: celecoxib and valdecoxib, both from Pfizer Inc. Analysis of the safety data from the Merck-funded...

  • Rofecoxib and celecoxib users with prior MI at risk for another.  // Reactions Weekly;3/17/2007, Issue 1143, p4 

    The article discusses research being done on elderly patients who may have an increased risk of acute myocardial infarction (MI) due to their history of MI and their use of rofecoxib and celecoxib. It references a study by J. M. Brophy, L. E. Lévesque and B. Zhang, that was published in a...

  • VALsartan In Acute myocardial iNfarcTion (VALIANT) trial: baseline characteristics in context. Velazquez, Eric J.; Pfeffer, Marc A.; McMurray, John V.; Maggioni, Aldo P.; Rouleau, Jean-Lucien; Van de Werf, Frans; Kober, Lars; White, Harvey D.; Swedberg, Karl; Leimberger, Jeffrey D.; Gallo, Paul; Sellers, Mary Ann; Edwards, Susan; Henis, Marc; Califf, Robert M.; VALIANT Investigators, for the // European Journal of Heart Failure;Aug2003, Vol. 5 Issue 4, p537 

    Background: the VALsartan In Acute myocardial iNfarcTion (VALIANT) trial compared outcomes with: (1) angiotensin-converting enzyme inhibition (ACEI) with the reference agent captopril; (2) angiotensin-receptor blockade (ARB) with valsartan; or (3) both in patients with heart failure (HF) and/or...

  • Glycoprotein IIb/IIIa Inhibitors in Patients Undergoing Percutaneous Mechanical Intervention for Acute Myocardial Infarction. Antoniucci, David // Current Medicinal Chemistry - Cardiovascular & Hematological Age;Jul2005, Vol. 3 Issue 3, p173 

    Limitations in study designs and adoption of rigid criteria for randomization in clinical trials on acute myocardial infarction (AMI) may result in the enrolment of artificial populations, and subsequent trial results may be misleading in many ways rendering problematic the generalization of the...

  • Estrogen doesn't protect against heart disease, but….  // Contemporary OB/GYN;Apr2006, Vol. 51 Issue 4, p14 

    Reports on the results of a research conducted by the Women's Health Initiative, regarding the health impacts of unopposed equine estrogen between women aged 50 to 70 in the U.S. in 2006. Involvement of an estimated 10,000 older women in the study; Occurrence of 201 coronary diseases in a group...

  • Incidence of Atrial Fibrillation in Patients with either Heart Failure or Acute Myocardial Infarction and Left Ventricular Dysfunction: A Cohort Study. Schmiegelow, Michelle D.; Pedersen, Ole D.; Køber, Lars; Seibæk, Marie; Abildstrøm, Steen Z.; Torp-Pedersen, Christian // BMC Cardiovascular Disorders;2011, Vol. 11 Issue 1, p19 

    Background: We examined the incidence of new-onset atrial fibrillation in patients with left ventricular dysfunction. Patients either had a recent myocardial infarction (with or without clinical heart failure) or symptomatic heart failure (without a recent MI). Patients were with and without...

  • Review: Low-molecular-weight heparin is effective and safe in the acute coronary syndromes.  // ACP Journal Club;Nov/Dec2003, Vol. 139 Issue 3, p58 

    This article focuses on the usage of low-molecular-weight heparins (LMWH) in the management of acute coronary artery syndromes (ACS) and percutaneous coronary intervention. Selected studies have included randomized controlled trials that have compared LMWH with unfractionated heparin (UFH) or...

  • Review: Low-molecular-weight herapin is effective and safe in the acute coronary syndromes: COMMENTARY. Hillegass, William B.; Brott, Brigitta C. // ACP Journal Club;Nov/Dec2003, Vol. 139 Issue 3, p58 

    Researcher G.C. Wong and colleagues have provided a systematic review of trials comparing low molecular weight heparin (LMWH) and un-fractionated heparin (UFH) in patients with acute coronary syndrome (ACS). In patients with unstable angina/non-ST-elevation myocardial infarction (UA/NSTEMI),...

  • Global Safety of Coxibs and NSAIDs. Pham, K.; Hirschberg, R. // Current Topics in Medicinal Chemistry;Jun2005, Vol. 5 Issue 5, p465 

    Non-steroidal anti-inflammatory drugs (NSAIDs) and selective cyclooxygenase-2 inhibitors (Coxibs) are commonly used for minor pain treatment and chronically in the management of rheumatoid arthritis and osteoarthritis. Three areas of safety concerns are shared by both groups of drugs:...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics